US Supreme Court rules in favor of Bayer in glyphosate jurisdiction dispute
By
Jost Maurin
Summary
The US Supreme Court ruled in favor of Bayer in the ongoing legal dispute over its glyphosate-based pesticide Roundup. The ruling did not address whether glyphosate causes cancer, but rather focused on jurisdictional issues — specifically that federal law preempts state-level failure-to-warn claims. This decision effectively removes the legal foundation for thousands of pending lawsuits against Bayer, which had faced billions in potential damages over claims that the weedkiller causes cancer.
Source
Key quotes
· 3 pulledDer Supreme Court entzieht Tausenden Glyphosat-Klagen gegen Bayer die rechtliche Grundlage
Es ging nicht um Krebsrisiken, sondern um Zuständigkeiten.
Der Bayer-Konzern siegt im Streit über sein Pestizid Glyphosat vor dem obersten US-Gericht.
You might also wanna read
Supreme Court to Hear Arguments in Roundup Weedkiller Cancer Lawsuit Against Bayer
The Supreme Court is set to hear arguments in a landmark case that could determine the fate of tens of thousands of lawsuits against Bayer c

Supreme Court restricts thousands of Roundup cancer lawsuits against Monsanto
The Supreme Court has blocked thousands of product liability lawsuits against Monsanto that claimed the company failed to warn consumers abo
Satirical Court Ruling Orders God to Add Cancer Warning to Earth
A satirical legal ruling from the Celestial Court orders God to add a cancer warning label to Earth, citing unsafe levels of carcinogens in
2000 Glyphosate Safety Study Retracted After 25 Years Due to Integrity Concerns
A 2000 study concluding glyphosate was safe has been retracted 25 years after publication due to "critical issues that undermine the academi
Thousands of U.S. farmers have Parkinson's. They blame a deadly pesticide
Satirical Article: EPA Falsely Reported to Approve Napalm as Pesticide
A satirical article reporting that the EPA has approved napalm as a pesticide for agricultural use, with Administrator Lee Zeldin claiming i

Comments
Sign in to join the conversation.
No comments yet. Be the first.